This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Building, Managing & Maintaining Critical Relationships With Key Opinion Leaders (KOLs)

CHAPEL HILL, N.C., Dec. 13, 2013 /PRNewswire/ -- In today's pharmaceutical marketplace, an organization's success is closely linked to their ability to build, maintain, and manage relationships with Key Opinion Leaders (KOLs). KOLs play a critical role in educating the medical and scientific communities and in building awareness about the latest medical therapies and novel mechanisms of action. As KOL relationship management continues to change, leaders must learn how to maximize their KOL relationships to benefit their own products and therapies.

To help pharmaceutical executives to navigate and understand the activities of effective KOL management programs at leading organizations, research and consulting firm Best Practices, LLC conducted a research study.  The report, "Optimizing Key Opinion Leaders Relationships: Best Practices in KOL Management," identifies the organizational structures, management strategies and tactics, and critical success factors associated with KOL management excellence. Executives can use this benchmarking research to learn best practices in KOL management and to discover how they can better approach KOL management within their organization.

Key study topics include:

  • KOL Segmentation and Behavior Drivers 
  • KOL Roles Over Product Lifecycle 
  • KOL Management Models 
  • Role of Medical Science Liaisons (MSLs) in Managing KOLs 
  • Emerging Trends and Innovative Practices in KOL Management 
  • Critical Success Factors in KOL Management 
  • Most Difficult Challenges in KOL Management

This benchmarking research drew participation from 36 respondents from 30 different companies. More than 80% of respondents were from Medical Affairs or Clinical Affairs departments.

To access the full report, or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1255.htm.

For more information on other recent primary research studies, contact us at 919.403.0251. For related research, visit our Best Practices, LLC website at http://www.best-in-class.com.

ABOUT BEST PRACTICES, LLCBest Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.

SOURCE Best Practices, LLC

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs